Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: A computer record-linkage study

British Journal of Cancer

Volumn 93, Issue 4, 2005, Pages 392-398

  Chen, W ^a   Petitti, D B ^a   Geiger, A M ^a  

^a Research and Evaluation   (United States)

Author keywords

All cause mortality; Breast cancer; Breast cancer mortality; Oestrogen; Oestrogen plus progestin

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; AGED; BREAST TUMOR; CANCER STAGING; ESTROGEN THERAPY; MEDICAL RECORD; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDICAL RECORD LINKAGE; MIDDLE AGED; MORTALITY; NEOPLASM STAGING; PROGESTINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 24944516302     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602701     Document Type: Article

References (29)

1. Antonie C, Liebens F, Carly B, Pastijn A, Rozenbarg S (2004) Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 19: 741-756
2. Barrett-Connor E (1991) Postmenopausal estrogen and prevention bias. Ann Intern Med 115: 455-456
3. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427
4. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen - progestogen replacement therapy. Am J Epidemiol 130: 221-228
5. Bundred NJ, Morris J (2003) Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet 362: 1329
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253
7. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593
8. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 12: 1175-1181
9. Ettinger B, Friedman GD, Bush T, Quesenberry Jr CP (1996) Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87: 6-12
10. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769-1775
11. Henderson BE, Paganini-Hill A, Ross RK (1991) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75-78
12. Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16: 3115-3120
13. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10: 2751-2760
14. Hunt K, Vessey M, McPherson K (1990) Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 97: 1080-1086
15. Jernstrom H, Frenander J, Ferno M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80: 1453-1458
16. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB (2003) Expression profiling of human breast cancers and gene regulation by progesterone recptors. J Mammary Gland Biol Neoplasiar 8: 257-268
17. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB (2005) Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19: 574-587
18. Nanda K, Bastian LA, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186: 325-334
19. Pappo I, Meirshon I, Karni T, Siegelmann-Danielli N, Stahl-Kent V, Sandbank J, Wasserman I, Halevy A (2004) The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers. Ann Surg Oncol 11: 52-58
20. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67: 327-332
21. Petitti DB (1994) Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 4: 115-118
22. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U (2002) Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9: 266-271
23. Sartorius CA, Shen T, Horwitz KB (2003) Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xengrafts. Breast Cancer Res Treat 79: 287-299
24. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91: 264-270
25. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR (1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127: 973-980
26. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352: 1965-1969
27. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN (1995) Evidence of a healthy estrogen user survivor effect. Epidemiology 6: 227-231
28. Willis DB, Calle EE, Miracle-McMahill HL, Heath Jr CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7: 449-457
29. Wu J, Richer J, Horwitz KB, Hyder SM (2004) Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res 64: 2238-2244